Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast
17 October 2019 - 11:00PM
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology
company focused on discovering and developing novel biologic
therapeutics to treat rare immune-mediated diseases, today
announced that it will release its financial results for the third
quarter ended September 30, 2019 before the U.S. financial markets
open on Thursday, October 31, 2019.
Management will host a conference call on
October 31, 2019 at 8:30 a.m. ET to discuss these results and
provide an update on the company. To access the call, please dial
(877) 224-9084 (domestic) or (720) 545-0022 (international) prior
to the scheduled conference call time and provide the access code
3067995. A live webcast of the call will be available on the
"Investors" section of the company's website,
www.momentapharma.com. An archived version of the webcast will be
posted on the Momenta website approximately two hours after the
call.
About MomentaMomenta
Pharmaceuticals is a biotechnology company with a validated
innovative scientific platform focused on discovering and
developing novel therapeutics to treat rare, immune-mediated
diseases and advancing its late stage biosimilar portfolio. The
company is headquartered in Cambridge, MA.
To learn more about Momenta, please visit
www.momentapharma.com, which does not form a part of this press
release.
Momenta’s logo, trademarks, and service marks
are the property of Momenta Pharmaceuticals, Inc. All other trade
names, trademarks, or service marks are property of their
respective owners.
Forward-Looking Statements
Statements in this press release regarding management's future
expectations, beliefs, intentions, goals, strategies, plans or
prospects, are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including but not
limited to statements about the use efficacy, safety, tolerability,
convenience and commercial potential of our product candidates,
including their potential as best-in-class agents. Forward-looking
statements may be identified by words such as "believe,"
"continue," “plan to”, "potential," "will," and other similar words
or expressions, or the negative of these words or similar words or
expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors, including
the risk of the unpredictable nature of early stage development
efforts for our product candidates; safety, efficacy or
tolerability problems with our product candidates; unexpected
adverse clinical trial results; and those referred to under the
section "Risk Factors" in the Company's Quarterly Report on Form
10-Q for the quarter ended June 30, 2019 filed with the Securities
and Exchange Commission, as well as other documents that may be
filed by the Company from time to time with the Securities and
Exchange Commission. As a result of such risks, uncertainties and
factors, the Company's actual results may differ materially from
any future results, performance or achievements discussed in or
implied by the forward-looking statements contained herein. The
Company is providing the information in this press release as of
this date and assumes no obligations to update the information
included in this press release or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact: Patty Eisenhaur
Momenta Pharmaceuticals1-617-395-5189IR@momentapharma.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2024 to May 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From May 2023 to May 2024